Systemic Therapy in BRAF V600E-Mutant Metastatic Colorectal Cancer: Recent Advances and Future Strategies

Purpose of Review: This review seeks to detail the clinical and pathologic features specific to BRAF^V600E colorectal cancer. Application of novel preclinical findings translated into the clinic for the development of new therapeutic options for patients with BRAF^V600E metastatic colorectal cancer will be detailed. Recent Findings: While BRAF inhibitors as monotherapy do not have the same clinical activity for colorectal cancer relative to other solid tumors harboring an oncogenic BRAF^V600E mutation, combination approaches targeting BRAF + MEK + EGFR hold promise for patients with BRAF^V600E colorectal cancer. Summary: Simultaneous targeting of multiple drivers along the MAPK pathway improves clinical outcomes for patients with BRAF^V600E colorectal cancer. Targeted therapies and immunotherapy hold great promise in the years to come for patients with this subtype of colorectal cancer.